A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy - Full Text View

Purpose

The purpose of this study is to determine whether Sativex® and GW-2000-02 are effective in the management of subjects with intractable cancer-related pain.

Condition	Intervention	Phase
Palliative Care Pain Cancer	Drug: Placebo Drug: Sativex® Drug: THC Alone	Phase 3

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Supportive Care
Official Title:	A Double Blind, Randomized, Parallel Group, Placebo Controlled, Comparative Study of the Efficacy, Safety and Tolerability of Cannabis Based Medicine (CBM) Extracts in Patients With Cancer-related Pain.

Resource links provided by NLM:

MedlinePlus related topics: Cancer Palliative Care

U.S. FDA Resources

Further study details as provided by GW Pharmaceuticals Ltd.:

Primary Outcome Measures:

The Change in Mean Pain Numerical Rating Scale (NRS) Score From Baseline to the End of the Treatment. [ Time Frame: 2 weeks: baseline - end of week 2 (last 3 days of treatment) ] [ Designated as safety issue: No ]
The pain NRS was complete at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate the number that best describes your pain or average pain in the last 24 hours" where 0 = no pain and 10 = pain as bad as you can imagine. No pain relates to the time prior to the onset of pain due to cancer. A negative value indicates an improvement in pain score from baseline.
The Consumption of Escape Analgesic Medication. [ Time Frame: 2 weeks: baseline - end of week 2 (last 3 days of treatment) ] [ Designated as safety issue: No ]
Subjects recorded their use of escape medication each day on their diary card.

Secondary Outcome Measures:

Sleep Disturbance 0-10 Numerical Rating Scale [ Time Frame: 2 weeks: baseline to end of week 2 (last 3 days of treatment) ] [ Designated as safety issue: No ]
The sleep disruption NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how your pain disrupted your sleep last night?" where 0 = did not disrupt sleep and 10 = completely disrupted (unable to sleep at all). A negative value indicates an improvement in sleep disruption score from baseline.
Nausea 0-10 Numerical Rating Scale [ Time Frame: 2 weeks; baseline - end of week 2 (last 3 days of treatment) ] [ Designated as safety issue: No ]
The nausea NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how sick you felt throughout the day?" where 0 = not sick at all and 10 = very sick. A negative value indicates an improvement in nausea score from baseline.
Memory 0-10 Numerical Rating Scale [ Time Frame: 2 weeks: baseline - end of week 2 (last 3 days of treatment) ] [ Designated as safety issue: No ]
The memory NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how well you are able to remember what you have done in the past 24 hours?" where 0 = very well and 10 = not at all. A negative value indicates an improvement in memory score from baseline.
Appetite 0-10 Numerical Rating Scale [ Time Frame: 2 weeks: baseline - end of week 2 (last 3 days of treatment) ] [ Designated as safety issue: No ]
The appetite NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how your appetite has been throughout the day?" where 0 = very good and 10 = very poor. A negative value indicates an improvement in appetite score from baseline.
Concentration 0-10 Numerical Rating Scale [ Time Frame: 2 weeks: baseline - end of week 2 (last 3 days of treatment) ] [ Designated as safety issue: No ]
The concentration NRS was completed at the same time each day, i.e. bedtime in the evening. The patient was asked "on a scale of '0 to 10', please indicate how well have you been able to concentrate throughout the day e.g. when reading a newspaper?" where 0 = very well and 10 = not at all. A negative value indicates an improvement in concentration score from baseline.
EORTC Quality of Life Questionnaire (EORTC-QLQC30) [ Time Frame: 2 weeks; baseline and end of treatment (2 weeks) ] [ Designated as safety issue: No ]
Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), a core cancer-specific questionnaire containing 30 items on patients' functioning, global quality of life, disease- and treatment related symptoms. Higher scores indicate a greater degree of symptoms, min.: 0, Max.: 100
Brief Pain Inventory Short Form [ Time Frame: End of 2 weeks ] [ Designated as safety issue: No ]
The BPI-SF is a 14-item questionnaire that asks patients to rate pain over the prior week and the degree to which it interferes with activities on a 0 to 10 scale, where 0=no pain and 10=pain as bad as you can imagine. Severity is measured as worst pain, least pain, average pain, and pain right now. The severity composite score was calculated as the arithmetic mean of the four severity items(range 0-10). The minimum value is zero and maximum is 10. A higher score represents a poor outcome.

Enrollment:	177
Study Start Date:	February 2002
Study Completion Date:	March 2004
Primary Completion Date:	February 2004 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Placebo Comparator: Placebo Placebo control	Drug: Placebo Containing colourants and excipients. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations in 24 hours. Other Name: GW-4000-01
Experimental: Sativex Active treatment	Drug: Sativex® Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours. Other Name: GW-1000-02
Experimental: THC Alone Active treatment	Drug: THC Alone Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours. Other Names: GW-2000-02 THC

Detailed Description:

This is a two week (two days baseline and two weeks treatment period), multicentre, double blind, randomised, placebo controlled, parallel group study to evaluate the efficacy of Sativex® and GW-2000-02 in subjects with cancer-related pain. Subjects are screened to determine eligibility and completed a two-day baseline period. Subjects then return to the centre for assessment, randomisation and dose introduction. All subjects are allowed to continue using all their current medications, provided that the dose remains stable throughout the study period. Their progress is reviewed after seven to 10 days and at the end of the study (day 14 to 20), or upon withdrawal. Subjects in this study are given the opportunity to be enrolled in an open label extension study (GWEXT0101).

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Willing and able to give informed consent.
Male or female, age 18 years or above.
Diagnosed with cancer of any type, which is considered to be terminal.
Diagnosed with cancer-related pain which is not wholly alleviated with their current strong opioid treatment and whose level of pain measured on a NRS is ³four on at least one occasion per day, during the two day run-in period, leading up to visit 1.
On strong opioid maintenance therapy for at least seven days prior to the screening visit.
Willing to abstain from any use of cannabis during the study, other than the study medication.
No cannabinoids use (cannabis, Marinol® or Nabilone) for at least seven days before Visit 1 and willing to abstain from any use of cannabis during the study.
Clinically acceptable blood results at the screening visit.
Able (in the investigators opinion) and willing to undertake and comply with all study requirements.
Willing to allow their own general practitioner, and consultant if appropriate, to be informed of study participation.
Willing for the Home Office to be notified of his or her participation in the study (applicable to the UK centres only).

Exclusion Criteria:

Know history of substance misuse.
Known or suspected to have had an adverse reaction to cannabinoids causing psychosis or other severe psychiatric illness.
Received any epidural analgesia within 48 hours prior to study entry.
Either received, within two weeks of study entry, or due to receive chemotherapy or radiotherapy during the study.
Unable to give informed consent.
History of any type of schizophrenia, any other psychotic illness, a serious personality disorder, or other significant psychiatric illness other than depression associated with their chronic pain and/or in response to the underlying condition.
Currently taking levodopa (Sinemet®, Sinemet plus®, Levodopa®, L-dopa®, Madopar®, Benserazide®).
Had a serious cardiovascular disorder, including angina, uncontrolled hypertension, or an uncontrolled symptomatic cardiac arrhythmia.
Significant renal or hepatic impairment, who in the opinion of the investigator, were unsuitable for treatment with study medication.
History of epilepsy.
Had oral cavity cancers or whose previous treatments had included radiotherapy to the floor of the mouth.
Female subjects who were pregnant or lactating or of child-bearing potential and were inadequately protected against conception during the study and for three months thereafter.
Male subjects who were sexually active and who were not using adequate forms of contraception during the study and for three months thereafter.
Subjects who had participated in a clinical research study in the past four weeks, prior to study entry.
Planned travel outside the UK during the study (applicable to the UK centres only).
Subjects who, in the opinion of the investigator, were unsuitable to participate in the study for any other reason, not mentioned in the entry criteria.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00674609

Locations

United Kingdom
Shropshire and Mid-Wales Hospice
Shrewsbury, United Kingdom, SY3 8HS

Sponsors and Collaborators

GW Pharmaceuticals Ltd.

Investigators

Principal Investigator:

Jeremy R Johnson, MB ChB

Shropshire and Mid-Wales Hospice

More Information

No publications provided

Responsible Party:	Mr Richard Potts/ Clinical Operations Director, GW Pharmaceuticals Ltd.
ClinicalTrials.gov Identifier:	NCT00674609 History of Changes
Other Study ID Numbers:	GWCA0101
Study First Received:	April 28, 2008
Results First Received:	July 5, 2012
Last Updated:	August 14, 2012
Health Authority:	United Kingdom: Medicines and Healthcare Products Regulatory Agency Romania: National Medicines Agency Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment

Keywords provided by GW Pharmaceuticals Ltd.:

Palliative Care
Pain
Cancer

Additional relevant MeSH terms:

Tetrahydrocannabinol
Hallucinogens
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses

Psychotropic Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on May 19, 2013

A Study of Sativex® for Pain Relief in Patients With Advanced Malignancy (SPRAY)